Literature DB >> 11320680

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors?

A K Dalfen1, D E Stewart.   

Abstract

OBJECTIVE: To ascertain the risk factors associated with the development of severe and fatal adverse drug reactions (ADRs) or intentional overdoses by patients on selective serotonin reuptake inhibitors (SSRIs).
METHODS: We undertook a data analysis of Health Canada's database of Adverse Drug Reactions to SSRIs from 1986 to 1996, as well as a literature review.
RESULTS: Among the complete ADR reports in the SSRI database, there were no sex differences in occurrences of all ADRs (n = 1011), severe ADRs (n = 295), drug-drug interactions (n = 312), deaths (n = 87), or intentional overdoses (n = 79), when sex differences in prescription practices were considered. There were no differences in ADR rates among different SSRIs. The most common cause of death among patients taking SSRIs was intentional overdose (n = 65, 74.7%). This was reported in 47 (72.3%) women and 18 (27.7%) men. The most common drugs taken with SSRIs in patients who died of intentional overdoses were benzodiazepines, tricyclic antidepressants (TCAs), narcotics, alcohol, and diphenhydramine. Patients who had severe or fatal ADRs were more likely to be taking an SSRI with 2 or more other drugs, including alcohol. Drug combinations that included another CYP-450 drug were especially problematic. A total of 129 cardiovascular ADRs were reported, most of which were severe. These included rhythm disturbances, blood pressure perturbations, and chest pain or angina. Cardiovascular ADRs most often occurred with concomitant drug use of benzodiazepines, TCAs, histamine H2 antagonists, lithium, and calcium channel blockers. There were 3 deaths from malignant neuroleptic syndrome unassociated with intentional overdose.
CONCLUSIONS: SSRIs are relatively safe when their widespread use is compared with the prevalence of ADRs. SSRIs may, however, be associated with ADRs, and even death, following intentional overdose or when taken with 2 or more other drugs or alcohol (particularly another drug metabolized by CYP-450). Physicians prescribing SSRIs need to consider drug-drug interactions and carefully monitor patients with severe affective disorders, comorbid medical conditions (especially cardiovascular disease), alcohol abuse, or a history of overdosing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320680     DOI: 10.1177/070674370104600306

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  8 in total

Review 1.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

2.  Bibliotherapy as a treatment for depression in primary care.

Authors:  Elizabeth V Naylor; David O Antonuccio; Mark Litt; Gary E Johnson; Daniel R Spogen; Richard Williams; Catherine McCarthy; Marcia M Lu; David C Fiore; Dianne L Higgins
Journal:  J Clin Psychol Med Settings       Date:  2010-09

3.  Assessment of the Antidepressant Side Effects Occurrence in Patients Treated in Primary Care.

Authors:  Enisa Ramic; Subhija Prasko; Larisa Gavran; Emina Spahic
Journal:  Mater Sociomed       Date:  2020-06

Review 4.  Treating depressed children with antidepressants: more harm than benefit?

Authors:  David Antonuccio
Journal:  J Clin Psychol Med Settings       Date:  2008-06

Review 5.  Abuse and misuse of antidepressants.

Authors:  Elizabeth A Evans; Maria A Sullivan
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

6.  Depression.

Authors:  Donna E Stewart; Enza Gucciardi; Sherry L Grace
Journal:  BMC Womens Health       Date:  2004-08-25       Impact factor: 2.809

7.  Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE.

Authors:  Sathvik Belagodu Sridhar; Sura Saad Faris Al-Thamer; Riadh Jabbar
Journal:  J Basic Clin Pharm       Date:  2016-06

8.  Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium.

Authors:  Grace Chen; George G Nomikos; John Affinito; Zhen Zhao
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.